🔗 Permalink

Assignee profile:

Io Therapeutics, Inc.

City:

Spring, Texas

Country:

United States

Published Applications:

Last publication date:

2024-06-20

Patent Grants:

Last grant date:

2025-06-10

Top Inventors for applications by Io Therapeutics, Inc.

These are the the leading inventors for applications assigned to Io Therapeutics, Inc.:

Roshantha A. Chandraratna 11 San Juan Capistrano, CA United States
Martin E. Sanders 8 Spring, TX United States
Martin E. Sanders 6 Seattle, WA United States
Randolph Noelle 5 Plainfield, NH United States

Elizabeth Nowak 5 West Lebanon, NH United States
Ethan DMITROVSKY 5 Hanover, NH United States
Powel H. Brown 3 Houston, TX United States
Vidyasagar Vuligonda 3 Spring, TX United States

Abhijit Mazumdar 2 Houston, TX United States
Harsh Shailesh Shah 2 Monroe, NJ United States
Shanming Kuang 2 Collegeville, PA United States
Vidyasagar Vuligonda 2 Lake Forest, CA United States

Cassandra Moyer 2 Houston, TX United States
Gabriel Ghiaur 1 Baltimore, MD United States
Roshantha A. Chandraratna 1 Spring, TX United States
Richard J. Jones 1 Baltimore, MD United States

Salvador Alonso 1 Baltimore, MD United States

Recent patent applications by Io Therapeutics, Inc.

Io Therapeutics, Inc. based in Spring, US has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:

#1 | 2024-06-20 ✅ Patent 12,325,685 granted on 2025-06-10

US20240199522A1

Chemistry; metallurgy

RXR AGONIST SALT FORM, POLYMORPHS THEREOF, AND USES THEREOF

#2 | 2024-02-15 ✅ Patent 12,115,193 granted on 2024-10-15

US20240050479A1

Human necessities

Methods of using RARγ agonists for cancer treatment

#3 | 2023-12-28 ✅ Patent 11,976,021 granted on 2024-05-07

US20230416190A1

Chemistry; metallurgy

Synthesis of tetrahydronaphthalenols and uses thereof

#4 | 2023-09-21 ✅ Patent 11,919,848 granted on 2024-03-05

US20230295069A1

Chemistry; metallurgy

RXR agonist salt form, polymorphs thereof, and uses thereof

#5 | 2023-06-08 ✅ Patent 11,998,521 granted on 2024-06-04

US20230172890A1

Human necessities

Use of an RXR agonist in treating drug resistant HER2+ cancers

#6 | 2023-06-08 ✅ Patent 11,896,558 granted on 2024-02-13

US20230172872A1

Human necessities

Use of an RXR agonist and taxanes in treating Her2+ cancers

#7 | 2023-03-30 ✅ Patent 11,793,835 granted on 2023-10-24

US20230095368A1

Human necessities

Methods of using RARγ agonists for cancer treatment

#8 | 2022-11-24 ✅ Patent 12,383,521 granted on 2025-08-12

US20220370386A1

Human necessities

TREATMENT OF DISEASES BY CONCURRENTLY ELICITING REMYELINATION EFFECTS AND IMMUNOMODULATORY EFFECTS USING SELECTIVE RXR AGONISTS

#9 | 2022-06-16 ✅ Patent 11,648,223 granted on 2023-05-16

US20220184012A1

Human necessities

Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy

#10 | 2022-05-19 ✅ Patent 11,793,781 granted on 2023-10-24

US20220151964A1

Human necessities

Autoimmune disorder treatment using RXR agonists

#11 | 2022-04-21 ✅ Patent 11,576,881 granted on 2023-02-14

US20220117922A1

Human necessities

Autoimmune disorder treatment using RXR agonists

#12 | 2021-06-03 ✅ Patent 11,690,831 granted on 2023-07-04

US20210161874A1

Human necessities

Treatment of autoimmune diseases with combinations of RXR agonists and thyroid hormones

#13 | 2021-05-13 ✅ Patent 11,224,583 granted on 2022-01-18

US20210137871A1

Human necessities

Use of an RXR agonist in treating HER2+ cancers

#14 | 2021-05-13 ✅ Patent 11,648,222 granted on 2023-05-16

US20210137866A1

Human necessities

Use of CYP26-resistant RAR alpha selective agonists in the treatment of cancer

#15 | 2021-05-06 ✅ Patent 11,246,845 granted on 2022-02-15

US20210128504A1

Human necessities

Autoimmune disorder treatment using RXR agonists

#16 | 2021-04-22 ✅ Patent 11,779,558 granted on 2023-10-10

US20210113507A1

Human necessities

Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy

#17 | 2021-04-22 ✅ Patent 11,737,996 granted on 2023-08-29

US20210113506A1

Human necessities

Immunomodulatory and differentiating function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy

#18 | 2021-04-08 ✅ Patent 11,786,555 granted on 2023-10-17

US20210100844A1

Human necessities

RAR selective agonists in combination with immune modulators for cancer immunotherapy

#19 | 2020-05-21 ✅ Patent 11,547,684 granted on 2023-01-10

US20200155489A1

Human necessities

Autoimmune disorder treatment using RXR agonists

#20 | 2019-03-21 ✅ Patent 11,517,549 granted on 2022-12-06

US20190083441A1

Human necessities

Treatment of disease with esters of selective RXR agonists

Also check out Io Therapeutics, Inc.'s (Spring, United States) applicant profile with 16 patent applications submitted.

AssigneeID:

353323 ⎘